Skip to main content
C

CONDUCTink

This biotechnology startup develops synthetic human tissues that mimic human physiology for drug discovery. These tissue-engineered biomaterials enable researchers to conduct more relevant drug discovery experiments.

Harrison Township, United StatesFounded 20232100+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current methods of preclinical drug discovery for diseases like Alzheimer's often rely on animal models that do not accurately replicate human physiology. This can lead to ineffective treatments advancing to clinical trials, resulting in wasted resources and prolonged timelines for patients. Existing in-vitro models often lack the complexity and functionality of real human tissues, limiting their predictive power.

Solution

CONDUCTink provides 3D-printed, bioengineered human tissue models that mimic human physiology for improved preclinical drug screening. Their technology allows for the creation of perfusable in-vitro models, including a blood-brain barrier model, enabling researchers to study drug interactions within a more realistic environment. By offering modality-agnostic, made-to-order tissue models and combinatorial delivery vehicles, CONDUCTink gives drug developers greater control and more relevant data during the drug discovery process. This approach aims to reduce reliance on animal models and accelerate the identification of promising therapeutic candidates.

Target Audience

CONDUCTink's primary customers are pharmaceutical companies and research institutions involved in preclinical drug discovery, particularly those focused on Alzheimer's disease and neurodegenerative disorders.

Features

  • 3D-printed, bioengineered human tissue models for in-vitro drug screening
  • Blood-brain barrier model with tunable topology and cell matrix interactions
  • Modality-agnostic platform allowing for customized tissue models
  • Combinatorial delivery vehicles for engineering biomaterial carriers
  • Capability to functionalize synthetic and natural biomaterial carriers for injectable therapeutics
  • Perfusable models that allow for the study of drug interactions in a realistic environment
This profile is AI-generated and may contain inaccuracies.